• To determination of the MTD and RDE based on DLTs during Cycle 1 (Phase Ia ) [ Time Frame: From baseline to Week 4 ]
  The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT).
• Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability of BR101801 when administered at the MTD or recommended dose (Phase Ia and Ib) [ Time Frame: through study completion, and about average of 1 year ]
  To evaluate safety and tolerability the aggregate review will include but is not limited to:

  • CTCAE TEAEs, treatment-related TEAEs, Grade 3 or higher TEAEs, Grade 3 or higher treatment-related TEAEs, serious treatment-related TEAEs, and TEAEs leading to death.
  • Laboratory results;
  • Vital signs;
  • ECGs;
  • Physical examination
  • ECOG performance status

• Cmax [ Time Frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15 ]
  Maximum concentration obtained directly from the observed concentration versus time data.
• AUC(0-inf) [ Time Frame: Cycle1( each cycle is 28 days) Day 1 ]
  Area under the plasma concentration-time curve from time zero extrapolated to infinity, calculated by linear up/log down trapezoidal summation
• AUC(0-last) [ Time Frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, Pre-dose to 24 hours after dosing ]
  Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration
• AUC(0-tau) [ Time Frame: Cycle1( each cycle is 28 days) Day 1 and Cycle 1( each cycle is 28 days) Day 15, dosing interval: 24 or 12 hours ]
  Area under the plasma concentration-time curve from time zero during a dosing interval
• Ae [ Time Frame: Cycle 1( each cycle is 28 days)Day 15, Pre-dose to 12 hours for BID dosing and Pre-dose to 24 hours for QD dosing ]
  Cumulative amount of unchanged drug excreted in urine

This is a Phase I, multi-center, open-label, FIH study comprising of 2 study parts (Phase Ia and Phase Ib).

The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of BR101801 in patients with relapsed/refractory advanced hematologic malignancies except acute leukemia and multiple myeloma.

The Phase Ib (dose expansion) part of the study is designed to assess tumor response and safety in specific advanced relapsed/refractory hematologic malignances at a dose of BR101801 identified in Phase Ia.

1. Phase Ia (Dose Escalation)

   Primary Objectives

   • To assess the safety and tolerability of BR101801 in patients with relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL.
   • To assess DLT and to determine the MTD and/or the RDE dose for BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.

   SecondaryObjectives

   • To characterize the plasma and urine PK of BR101801.
   • To assess the preliminary antitumor activity of BR101801.
2. Phase Ib (Dose Expansion)

Primary Objectives

•To assess the safety and tolerability of BR101801 at the RDE dose in patients with relapsed and/or refractory B-cell lymphoma, CLL/SLL, and PTCL.

SecondaryObjectives

• To assess clinical activity of BR101801 when administered orally on a daily schedule in 4-week cycles until disease progression.
• To assess the plasma PK of BR101801

OUTLINE: This is a Phase I, multi-center, open-label, FIH study. Safety monitoring committee (SMC) will be responsible for safety oversight.

• Diffuse Large B Cell Lymphoma
• Follicular Lymphoma
• Chronic Lymphocytic Leukemia
• Small Lymphocytic Leukemia
• B Cell Lymphoma
• Marginal Zone Lymphoma
• Waldenstrom Macroglobulinemia
• Peripheral T Cell Lymphoma

• Drug: BR101801 (Phase Ia)
  Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
• Drug: BR101801 (Phase Ib)
  Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.

• Experimental: Treatment ( BR101801):Phase Ia (dose escalation)
  Patients will receive BR101801 capsules orally, QD in 28-day cycles. The regimen may be changed to BID dosing based on emerging data.
  Intervention: Drug: BR101801 (Phase Ia)
• Experimental: Treatment ( BR101801):Phase Ib (dose expansion)

  Group A: Patients with diffuse large B-cell lymphoma (DLBCL) including MYC-altered DLBCL

  Group B: Patients with follicular lymphoma.

  Group C: Patients with chronic lymphocytic leukemia/small lymphocytic leukemia, other B-cell lymphoma such as, but not limited to mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, or PTCL

  Intervention: Drug: BR101801 (Phase Ib)

<Inclusion Criteria>

1. Patients must sign an informed consent document
2. Female or male patients aged ≥ 18 years.
3. ECOG performance status ≤ 2.
4. Life expectancy more than 3 months.
5. Phase Ia:Patients with relapsed and/or refractory relapsed/refractory B-cell lymphoma, CLL/SLL, and PTCL diagnosed with World Health Organization (WHO) classification

6. Phase Ib:

   • Group A: Patients with DLBCL including MYC-altered DLBCL and transformed DLBCL.
   • Group B: Patients with follicular lymphoma Grade 1 to 3a
   • Group C: Patients with CLL/SLL, other B-cell lymphoma such as, but not limited to, mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia, and PTCL
7. Patients have measurable disease based on the appropriate tumor type criteria( Phase Ib only)

<Exclusion Criteria>

1. Presence of overt leptomeningeal or active CNS metastases, or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks. Patients with treated brain metastases should be neurologically stable and off steroids for at least 2 weeks before administration of any study treatment.
2. Impaired cardiac function or clinically significant cardiac disease
3. Patients with interstitial pneumonia or history of drug-induced interstitial pneumonia/pneumonitis.
4. Human immunodeficiency virus (HIV) infection.
5. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus antibody (HCVAb).
6. Chronic liver disease or chronic hepatitis
7. Any gastrointestinal disorders interfering with study drug absorption or are unable to swallow tablets or capsules.
8. Malignant disease, other than that being treated in this study.

9. For patients with lymphoma:

   • Systemic antineoplastic therapy or any experimental therapy within 3 weeks or 5 half lives, whichever is shorter, before the first dose of study treatment.

11.Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (≥ 10 mg/day prednisone or equivalent).

12.Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment.

13.Use of hematopoietic colony-stimulating growth factors, thrombopoietin mimetics, or erythroid-stimulating agents ≤ 2 weeks prior to start of study drug.

14.Patients with a history of stroke or having active neurological symptoms, with the exception of chronic conditions which, in the opinion of the neurologist, Investigator, and the Sponsor, would not impact ongoing neurologic assessments while on study treatment.

15.Active infection requiring systemic or antiviral antibiotic therapy. 16.Major surgery within 2 weeks of the first dose of study treatment 17.Radiotherapy within 2 weeks of the first dose of study drug, except for palliative radiotherapy to a limited-field, such as for the treatment of bone pain or a focally painful tumor mass.

18.Presence of CTCAE ≥ Grade 2 toxicity due to prior cancer therapy. 19.Participation in an interventional, investigational study within 2 weeks or 5 half-lives, whichever is shorter, of the first dose of study treatment.

20.Any medical condition that would, in the Investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results.